ClinicalTrials.gg
RecruitingNCT07885683Updated Nov 18, 2026

MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA)

A Phase 1/2 interventional study of The MagSense® HER2 Imaging Agent (MSH2IA) in HER2-positive Breast Cancer, sponsored by Imagion Biosystems, Inc.. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Imagion Biosystems, Inc. · Phase 1/2, Interventional, and Diagnostic

How we know

Updated Nov 18, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This Phase 1b/2 study is designed as an open-label, multicenter, 3 group, interventional study in which Phase 1b will evaluate the pharmacokinetics (PK) of MSH2IA and Phase 2 will confirm lowest effective dose as well as evaluate image timing, and diagnostic performance of a selected dose of MSH2IA when administered by subareolar or peritumoral injection.

No hypothesis testing is planned. Comparative statistics will be used to generate hypotheses to be tested in subsequent studies.

02

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 70 is close to the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

This is the only study on the registry with Imagion Biosystems, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants ≥18 years of age and are willing to provide written .
  2. In the opinion of the Investigator, willing and able to comply with required study procedures.
  3. confirmed primary + breast cancer; participants with a second primary tumor in the contralateral breast are eligible, but only 1 side will be evaluated.
  4. Primary tumor must be HER2+, defined according to ASCO/CAP 2018 guidelines as either IHC 3+ or IHC 2+ with confirmatory ISH-positive.
  5. Phase 1b and Phase 2 (Imaging Schedule) participants must be node suspicious by SOC assessment.
  6. No previous treatment of the primary tumor or ipsilateral axilla that includes surgery (other than ), radiotherapy, or a biologic such as trastuzumab. In Phase 2 (Diagnostic Performance) only, participants who have received NCT are eligible if treatment has not included trastuzumab.
  7. Female participants of nonchildbearing potential: defined as either surgically sterilized (eg, hysterectomy, bilateral salpingectomy, bilateral oophorectomy ≥6 weeks before screening) or (ie, no menses for 12 months without an alternative medical cause.
  8. Female participants of are eligible to participate if not pregnant, not breastfeeding, and using .

Exclusion criteria

Exclusion Criteria:

Participants will be excluded from the study if ANY of the following criteria are applicable:

  1. to the use of the Magtrace™ and Sentimag® Magnetic Localization System (Magtrace 2018), including use before NCT when MRI will be the primary imaging method for evaluation of breast cancer
  2. Previous or current diseases of Fe metabolism or history of adverse reactions to intravenous Fe products
  3. Known to trastuzumab, iron oxide, or polyethylene glycol compounds
  4. Treatment by Herceptin® or biosimilar within prior six months
  5. Planned or prior use of Magtrace™ and Sentimag as a diagnostic agent, as it might interfere with MagSense® evaluations
  6. Known clinical or radiological evidence of distant (Stage IV disease)
  7. Inflammatory breast cancer
  8. Prior surgical axillary procedure, including SLNB or ALND, or previous radiation on the ipsilateral side of the breast cancer primary
  9. Prior history of breast cancer in the ipsilateral breast
  10. Metal devices or fragments other than post-breast clips in the ipsilateral axilla or in the ipsilateral chest
  11. Any contraindications to MRI imaging
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Phase 1b - MSH2IA Pharmacokinetics

    Participants enrolled in Phase 1b will receive MSH2IA to evaluate its pharmacokinetic (PK) profile.

    Combination Product: The MagSense® HER2 Imaging Agent (MSH2IA)

  • Experimental
    Phase 2 - MSH2IA Dose and Diagnostic Performance

    Participants enrolled in Phase 2 will receive MSH2IA via subareolar or peritumoral injection to confirm the lowest effective dose, evaluate image timing, and assess the diagnostic performance of a selected dose of MSH2IA.

    Combination Product: The MagSense® HER2 Imaging Agent (MSH2IA)

Interventions

  • Combination productThe MagSense® HER2 Imaging Agent (MSH2IA)

    Imaging Agent intended as an adjunct to MRI for the assessment of axillary nodal disease in participants diagnosed with HER2+ primary breast cancer.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Level of Fe in blood

    PK MSH2IA Fe concentration \> LLOQ in human whole blood

    Time frame: 24 hours post injection

  2. Phase 2 (Imaging Schedule): Dose and Imaging schedule for MSH2IA

    MSH2IA dose to image suspicious versus normal nodes and Post dose MRI imaging timing

    Time frame: 24 hours post injection

  3. Phase 2 (Diagnostic Performance): Diagnostic performance comparison between MSH2IA and SOC

    Patient level concordance of MSH2IA imaging to clinical pathology and Patient level concordance of MSH2IA to AxUS as measured by PPV, NPV, and Overall Predictive Concordance (PPV+NPV).

    Time frame: 24 hours post injection

Secondary outcomes

  1. Safety and Tolerability of MSH2IA Across All Phases

    All Phases: Assess safety and tolerability of MSH2IA Incidence and severity of AEs, serious adverse events and Injection site reactions (ISRs)

    Time frame: From baseline through 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010 Apr 1;28(10):1684-91. doi: 10.1200/JCO.2009.24.9284. Epub 2010 Mar 1. PubMed 20194857 ↗
  • Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003 Aug 7;349(6):546-53. doi: 10.1056/NEJMoa012782. PubMed 12904519 ↗
  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707-12. doi: 10.1126/science.2470152. PubMed 2470152 ↗
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177-82. doi: 10.1126/science.3798106. PubMed 3798106 ↗
  • Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007 Apr 1;109(7):1255-63. doi: 10.1002/cncr.22540. PubMed 17330229 ↗
  • Sharifi N, Ahmad S. Breast cancer-related lymphedema: A critical review on recent progress. Surg Oncol. 2024 Oct;56:102124. doi: 10.1016/j.suronc.2024.102124. Epub 2024 Aug 23. PubMed 39208532 ↗
  • Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093. PubMed 10963602 ↗
  • Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010 Jul 10;28(20):3271-7. doi: 10.1200/JCO.2009.25.9820. Epub 2010 May 24. PubMed 20498394 ↗
  • Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748. doi: 10.1155/2014/852748. Epub 2014 Sep 7. PubMed 25276427 ↗
  • Harbeck N, Thomssen C. A new look at node-negative breast cancer. Oncologist. 2011;16 Suppl 1:51-60. doi: 10.1634/theoncologist.2011-S1-51. PubMed 21278441 ↗
  • Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995 Sep;222(3):394-9; discussion 399-401. doi: 10.1097/00000658-199509000-00016. PubMed 7677468 ↗
  • Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23. PubMed 23000897 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 26 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Oct 21, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jul 23, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added — first site in United States
Show site
  • Regis Clinical Research LLC · Miami, United States
Nov 18, 2026
Contact
Study contact changed: m•••@coh.org · •••8446→l•••@syneoshealth.com · •••8500. See the current contact
Nov 18, 2026
Registered
First appeared on the registry
Oct 21, 2026
Show all 2 updates
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Regis Clinical Research LLC · Miami, United States
    Contact Study contact changed: m•••@coh.org · •••8446→l•••@syneoshealth.com · •••8500. See the current contact
    + 2 other changes: verification date and responsible party
  2. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07885683
Lead sponsor
Imagion Biosystems, Inc.
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Jul 23, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Lisa Ince, B.S.
Contact
lisa.ince@syneoshealth.com
480-238-8500

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion